Equities Analysts Offer Predictions for LRMR FY2026 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Analysts at HC Wainwright issued their FY2026 earnings estimates for Larimar Therapeutics in a research note issued to investors on Thursday, July 2nd. HC Wainwright analyst R. Selvaraju expects that the company will earn ($1.60) per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($1.29) EPS.

LRMR has been the topic of a number of other research reports. Robert W. Baird dropped their target price on Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, June 30th. Citigroup reaffirmed a “buy” rating on shares of Larimar Therapeutics in a report on Tuesday, June 30th. Wall Street Zen upgraded shares of Larimar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Wedbush dropped their price objective on shares of Larimar Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $12.71.

Larimar Therapeutics Trading Down 0.1%

Larimar Therapeutics stock opened at $3.29 on Tuesday. Larimar Therapeutics has a twelve month low of $2.71 and a twelve month high of $6.42. The stock has a 50 day moving average of $3.62 and a two-hundred day moving average of $3.93. The stock has a market capitalization of $341.35 million, a price-to-earnings ratio of -1.58 and a beta of 0.83.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.22.

Institutional Trading of Larimar Therapeutics

A number of institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets grew its holdings in Larimar Therapeutics by 75.8% during the third quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock worth $33,000 after acquiring an additional 4,376 shares during the period. SG Americas Securities LLC acquired a new stake in Larimar Therapeutics in the fourth quarter valued at $60,000. Sei Investments Co. boosted its position in shares of Larimar Therapeutics by 54.5% during the 1st quarter. Sei Investments Co. now owns 16,336 shares of the company’s stock worth $74,000 after purchasing an additional 5,763 shares in the last quarter. Coldstream Capital Management Inc. purchased a new stake in shares of Larimar Therapeutics during the 3rd quarter worth $57,000. Finally, Strs Ohio grew its stake in shares of Larimar Therapeutics by 174.7% during the 1st quarter. Strs Ohio now owns 21,700 shares of the company’s stock worth $98,000 after purchasing an additional 13,800 shares during the period. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.